Lipodystrophy Pipeline | A Clinical Trials Analysis Report

10 Jun 2021
www.globenewswire.com
Gene TherapyOrphan Drug
Los Angeles, USA, June 09, 2021 (GLOBE NEWSWIRE) -- Lipodystrophy Pipeline | A Clinical Trials Analysis Report | DelveInsight The companies with their Lipodystrophy drug candidates in the most advanced stage (Phase III stage) include Ionis Pharmaceuticals, soon drifting the Lipodystrophy Pipeline landscape. DelveInsight's "Lipodystrophy Pipeline Insight" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Lipodystrophy pipeline landscapes. It comprises Lipodystrophy pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Lipodystrophy therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Lipodystrophy pipeline products. Some of the key takeaways from the Lipodystrophy Pipeline Report Get an overview of pipeline landscape @ Lipodystrophy Clinical Trials Analysis Lipodystrophy is a medical problem where there is an abnormal distribution of fat in the body. The condition is also characterised by a lack of circulating leptin, which may lead to osteosclerosis. Currently, there is no specific treatment, which will permanently replace adipose tissue. The Lipodystrophy treatment is focused on managing metabolic abnormalities to prevent complications and cosmetic appearance. Lipodystrophy Emerging Drugs IONIS-APOCIII-LRx, formerly known as AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to prohibit the production of apoC-III for patients who are at risk of condition due to increased triglyceride levels. ApoC-III is a protein produced in the liver that maintains triglyceride metabolism in the blood. The drug is currently being investigated in the Phase III stage of development to treat patients with Hyperlipoproteinaemia and Lipodystrophy. The U.S. FDA and European Medicines Agency have also granted the drug with the Orphan drug designation. Vupanorsen is an investigational antisense therapy founded by Ionis Pharmaceuticals and co-developed by Ionis and its subsidiary Akcea Therapeutics. Vupanorsen has been created using Ionis' advanced LIgand Conjugated Antisense (LICA) technology platform to prohibit the production of angiopoietin-like 3 (ANGPTL3) protein, which a vital regulator of triglyceride and cholesterol metabolism in the liver. Pfizer has started a Phase 2b study of vupanorsen in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs). REGN4461 is a leptin receptor (LEPR) agonist for lipodystrophy and obesity which is being developed by Regeneron Pharmaceuticals. It is currently in the Phase II stage of development. It is administered intravenously or subcutaneously. CGT2 was licensed from Lipigon Pharmaceuticals 2019; CombiGene expanded its scope to include metabolic diseases. The project's initial goal is to develop a gene therapy treatment for partial lipodystrophy, a very rare disease that today completely lacks adequate treatment. CGT2 is currently in the Preclinical stage of development. For further information, refer to the detailed report @ Lipodystrophy Pipeline Therapeutics Scope of Lipodystrophy Pipeline Drug Insight Key Questions regarding Current Lipodystrophy Treatment Landscape and Emerging Therapies Answered in the Pipeline Report Table of Contents Get a customised pipeline report @ Lipodystrophy Drugs Pipeline Report Related Reports DelveInsight's Lipodystrophy - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight' s HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. Lipodystrophy Market Research Report deliver an in-depth understanding of the Lipodystrophy Market Size, Share, Trends, Pipeline Therapies, Key Companies, and Epidemiology Forecast in the 7MM. DelveInsight's Lipodystrophy - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Lipodystrophy in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. DelveInsight's Liposarcoma Market Insights, Epidemiology and Market Forecast - 2030 report provides a depth understanding of historical and forecasted epidemiology. DelveInsight's Necrobiosis Lipoidica (NL) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. About DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.